Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Stocks - Europe Weakens Following Drug Trial Disappointment

Published 04/24/2020, 03:44 AM
Updated 04/24/2020, 03:48 AM
© Shutterstock

By Peter Nurse 

Investing.com - European stock markets pushed sharply lower Friday amid disappointment over the reduced likelihood of a quick end to the coronavirus outbreak and concerns at the European policy response to it.

At 4 AM ET (0800 GMT), the U.K.'s FTSE index traded 1.4% lower, France's CAC 40 and the DAX both fell 1.8%. The broader based Stoxx 600 Europe index dropped 1.3%. 

Doubts have emerged over the efficacy of Gilead Sciences’ (NASDAQ:GILD) antiviral drug remdesivir in treating the Covid-19, after the Financial Times reported overnight that it had failed its first randomized clinical trial.

Gilead disputed the report, saying that the trial was "inconclusive", but the news was taken badly as the drug was previously thought to be one of the best prospects for treating the virus and thus quickly bringing the pandemic to a close.

Markets were also disappointed by the failure of an EU summit to provide any details about a post-pandemic recovery fund, both as regards its size and the method of financing it. 

 European Central Bank President Christine Lagarde reportedly told the meeting that the European Union’s economy could shrink by as much as 15% this year. A best-case estimate was a contraction of 5% she added. 

EU Industry Commissioner Thierry Breton was slightly more optimistic Friday when he stated the EU was heading this year towards a 5%-10% economic contraction. 

"As of today, in the European Union, we're on course for a 5% to 10% (recession), meaning it's about 7.5%. But that is today, and if things don't improve and if we have a second peak (of the outbreak), things could get worse", Breton said on France 2 television.

The banking sector has been in the spotlight Friday, after Thursday’s move by S&P to cut Commerzbank (DE:CBKG)'s credit rating by a notch to BBB+, and lowered its outlook for Deutsche Bank (DE:DBKGn) to negative from stable. Commerzbank’s shares dropped 3.9% and Deutsche Bank shares fell 4.9%.

The oil market has pushed higher Friday, but still remains under pressure given the global supply glut. Eni shares fell 2.9% after the Italian major said first-quarter profit fell 94%, and cut its forecasts for production and capital spending further. 

Airline stocks were also under pressure after Lufthansa posted an operating loss of 1.2 billion euros in the first quarter and warned it could run out of cash within weeks. Lufthansa (DE:LHAG) shares fell 7.7% to their lowest in over 15 years.

At 4 AM ET, U.S. crude June futures traded 1.5% higher at $16.75 a barrel. The international benchmark Brent contract rose 1.4% to $21.63.

Elsewhere, gold futures rose 0.3% to $1,750.55/oz, while EUR/USD traded at 1.0764, down 0.3% on the day.

 

Latest comments

keep pumping out the hysteria articles. the common flu has been around for many many years and there is still no cure, it kills over 400,000 each year globally. you expect drug companies to pull one out their *****in a couple of months for this?  there are plenty of other much more deadly diseases out there that this time and money could be put to better use to find solutions for.
if you sit back and give it a deep thought about it, 5% is bad, but not as bad as some think it is. I mean, it might be bad if you make quadrilions on the stock market, but for a normal guy, 5% might be like a bicicle a year
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.